← Back

Amoy Diagnostics Co Ltd

Amoy Diagnostics Co., Ltd. is a Chinese company engaged in the research, development, production, sale, and support of tumor precision medical diagnostic products in China and internationally. Its product portfolio includes AmoyDx panels for homologous recombination deficiency (HRD), comprehensive genomic profiling, BRCA1/BRCA2 analysis, and various NGS and PCR assays for cancer-related gene mutations and fusions. The company also offers DNA and RNA extraction kits under the Super-ARMS and AmoyDx brands. Founded in 2008, Amoy Diagnostics is based in Xiamen, China.

Price · split & dividend adjusted
News & notes moving 300685.CS
300685.CS

Amoy Diagnostics 2026 Interim Report Net Profit 166 Million Yuan, Down 12.12% Year-on-Year

Amoy Diagnostics released its 2026 interim report, with net profit attributable to the parent company of 166 million yuan, a decrease of 12.12% compared with the same period last year. Total operating revenue was 559 million yuan, down 3.45% year-on-year; net cash inflow from operating activities was 195 million yuan. The latest gross margin was 83.41%, a decrease of 0.59 percentage points from the same period last year; diluted earnings per share was 0.42 yuan, down 12.50% year-on-year.
Jiemian·25dRead more →
300685.CS

Amoy Diagnostics Has Repurchased 8.55 Million Shares for 161 Million Yuan

Amoy Diagnostics announced that as of July 31, 2026, the company had repurchased 8.55 million shares, accounting for 2.19% of total share capital, with a total repurchase amount of 161 million yuan and a repurchase price range of 15.68 yuan to 22.53 yuan per share. In the first quarter of 2026, the company achieved revenue of 260 million yuan and net profit attributable to the parent company of 85.16 million yuan.
财中社·45dRead more →